J Aw-Zoretic1, D Seth2, G Katzman2, S Sammet2. 1. Department of Medical Imaging, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, United States. Electronic address: Jaw@luriechildrens.org. 2. Department of Radiology, University of Chicago, Chicago, IL, United States.
Abstract
PURPOSE: The purpose of this review is to determine the averaged effective dose and lifetime attributable risk factor from multiple head computed tomography (CT) dose data on children with ventriculoperitoneal shunts (VPS). METHOD AND MATERIALS: A total of 422 paediatric head CT exams were found between October 2008 and January 2011 and retrospectively reviewed. The CT dose data was weighted with the latest IRCP 103 conversion factor to obtain the effective dose per study and the averaged effective dose was calculated. Estimates of the lifetime attributable risk were also calculated from the averaged effective dose using a conversion factor from the latest BEIR VII report. RESULTS: Our study found the highest effective doses in neonates and the lowest effective doses were observed in the 10-18 years age group. We estimated a 0.007% potential increase risk in neonates and 0.001% potential increased risk in teenagers over the base risk. CONCLUSION: Multiple head CTs in children equates to a slight potential increase risk in lifetime attributable risk over the baseline risk for cancer, slightly higher in neonates relative to teenagers. The potential risks versus clinical benefit must be assessed.
PURPOSE: The purpose of this review is to determine the averaged effective dose and lifetime attributable risk factor from multiple head computed tomography (CT) dose data on children with ventriculoperitoneal shunts (VPS). METHOD AND MATERIALS: A total of 422 paediatric head CT exams were found between October 2008 and January 2011 and retrospectively reviewed. The CT dose data was weighted with the latest IRCP 103 conversion factor to obtain the effective dose per study and the averaged effective dose was calculated. Estimates of the lifetime attributable risk were also calculated from the averaged effective dose using a conversion factor from the latest BEIR VII report. RESULTS: Our study found the highest effective doses in neonates and the lowest effective doses were observed in the 10-18 years age group. We estimated a 0.007% potential increase risk in neonates and 0.001% potential increased risk in teenagers over the base risk. CONCLUSION: Multiple head CTs in children equates to a slight potential increase risk in lifetime attributable risk over the baseline risk for cancer, slightly higher in neonates relative to teenagers. The potential risks versus clinical benefit must be assessed.
Authors: Hedvig Hricak; David J Brenner; S James Adelstein; Donald P Frush; Eric J Hall; Roger W Howell; Cynthia H McCollough; Fred A Mettler; Mark S Pearce; Orhan H Suleiman; James H Thrall; Louis K Wagner Journal: Radiology Date: 2010-12-16 Impact factor: 11.105
Authors: William W Ashley; Robert C McKinstry; Jeffrey R Leonard; Matthew D Smyth; Benjamin C Lee; Tae Sung Park Journal: J Neurosurg Date: 2005-08 Impact factor: 5.115
Authors: A Ba-Ssalamaha; S Schick; K Heimberger; K F Linnau; N Schibany; R Prokesch; S Trattnig Journal: Magn Reson Imaging Date: 2000-04 Impact factor: 2.546